Chemoprevention for high-risk women: tamoxifen and beyond (Q34572541)

3 August 2017

title

Chemoprevention for high-risk women: tamoxifen and beyond (English)

1 reference

3 August 2017

1 reference

Fabian CJ

1 reference

3 August 2017

Kimler BF

series ordinal

1 reference

3 August 2017

publication date

1 September 2001

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

311-320

1 reference

3 August 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Anatomic markers of human premalignancy and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Selective estrogen receptor modulators: structure, function, and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Is tamoxifen effective in prevention of breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Reducing the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Assessing the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Validation of a breast cancer risk assessment model in women with a positive family history.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Validation studies for models projecting the risk of invasive and total breast cancer incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Simplified method of grading primary carcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Involvement of the polyamine pathway in breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Metalloproteinases: role in breast carcinogenesis, invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Balance of cell proliferation and apoptosis in breast carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Dysregulation of apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

The potential of aromatase inhibitors in breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Hormone replacement therapy as treatment of breast cancer--a phase II study of Org OD 14 (tibilone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

William L. McGuire Memorial Symposium. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2001.21570.X

10.1046/J.1524-4741.2001.21570.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference